

INDUSTRY PRACTICES REVIEW COMMITTEE

A LOOK AT CODE VIOLATIONS – January 1, 2003 to December 31, 2003

Year	Company	No.	Category of Violation	Report #
2003	AMGEN Canada Inc.	1	Advertising & Information Dissemination	48
	AstraZeneca Canada Inc.	1	Advisory Boards / Consultants	50
	Aventis Pharma Inc.	1	CHE	48
	Bayer Inc.	1	Post Registration Studies	49
	Bristol-Myers Squibb Canada Inc.	2	Service Oriented Items	48
	Bristol-Myers Squibb Canada Inc.	1	Post Registration Studies	48
	Eli Lilly Canada Inc.	1	Service Oriented Items	48
	Eli Lilly Canada Inc.	2	Reps. of Pharmaceutical Companies	49
	GlaxoSmithKline Inc.	1	Service Oriented Items	48
	GlaxoSmithKline Inc.	1	CHE	48
	Janssen-Ortho	2	Advertising & Information Dissemination	48
	Janssen-Ortho	1	Service Oriented Items	50
	Janssen-Ortho	1	Special Promotion	50
	Janssen-Ortho	1	Reps. of Pharmaceutical Companies	50
	Janssen-Ortho	2	Post Registration Studies	51
	Janssen-Ortho	1	Advertising & Information Dissemination	51
	Pharmacia Canada	1	Service Oriented Items	50
	Sanofi-Synthelabo Canada Inc.	1	Advertising & Information Dissemination	48
	Sanofi-Synthelabo Canada Inc.	1	Service Oriented Items	48
	Schering Canada Inc.	1	Service Oriented Items	48
	SOLVAY PHARMA Inc.	1	Service Oriented Items	49
	SOLVAY PHARMA Inc.	1	CHE	49
	Wyeth-Ayerst Canada Inc.	1	CHE	49